SG11201403169PA - Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders - Google Patents

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Info

Publication number: SG11201403169PA
Authority: SG; Singapore
Prior art keywords: treatment; pharmaceutical compositions; inflammatory disorders; dihydropyrimidinoisoquinolinones; novel
Prior art date: 2011-12-22

Application number

SG11201403169PA

Other languages

English (en)

Inventor

Frédéric Gilbert Labéguère

Gregory John Robert Newsome

Luke Jonathan Alvey

Laurent Raymond Maurice Sanière

Stephen Robert Fletcher

Original Assignee

Galapagos Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-12-22

Filing date

2012-12-20

Publication date

2014-07-30

2012-12-20 Application filed by Galapagos Nv filed Critical Galapagos Nv

2014-07-30 Publication of SG11201403169PA publication Critical patent/SG11201403169PA/en

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Pulmonology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Endocrinology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

SG11201403169PA 2011-12-22 2012-12-20 Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders SG11201403169PA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161578979P	2011-12-22	2011-12-22
PCT/EP2012/076275 WO2013092791A1 (en)	2011-12-22	2012-12-20	Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (1)

Publication Number	Publication Date
SG11201403169PA true SG11201403169PA (en)	2014-07-30

Family

ID=47520068

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201403169PA SG11201403169PA (en)	2011-12-22	2012-12-20	Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Country Status (35)

Country	Link
US (5)	US8927543B2 (zh)
EP (3)	EP4019519A1 (zh)
JP (1)	JP6062453B2 (zh)
KR (1)	KR102012268B1 (zh)
CN (1)	CN103998448B (zh)
AR (1)	AR089284A1 (zh)
AU (1)	AU2012357067B2 (zh)
BR (1)	BR112014015142B1 (zh)
CA (1)	CA2859578C (zh)
CL (1)	CL2014001664A1 (zh)
CO (1)	CO7010835A2 (zh)
CR (1)	CR20140305A (zh)
CY (1)	CY1119434T1 (zh)
DK (2)	DK3378862T3 (zh)
EA (1)	EA023826B1 (zh)
ES (2)	ES2911449T3 (zh)
HK (1)	HK1201528A1 (zh)
HR (2)	HRP20220456T1 (zh)
HU (1)	HUE12812237T4 (zh)
IL (2)	IL233212B (zh)
IN (1)	IN2014MN01033A (zh)
LT (2)	LT3378862T (zh)
MX (1)	MX351681B (zh)
NI (1)	NI201400060A (zh)
PE (1)	PE20141685A1 (zh)
PH (1)	PH12014501178B1 (zh)
PL (2)	PL3378862T3 (zh)
PT (2)	PT2794604T (zh)
SG (1)	SG11201403169PA (zh)
SI (2)	SI2794604T1 (zh)
TW (1)	TWI567073B (zh)
UA (1)	UA111767C2 (zh)
UY (1)	UY34545A (zh)
WO (1)	WO2013092791A1 (zh)
ZA (1)	ZA201404607B (zh)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE041509T2 (hu)	2011-12-22	2019-05-28	Janssen Biopharma Inc	Szubsztituált nukleozidok, nukleotidok és ezek analógjai
AR089284A1 (es)	2011-12-22	2014-08-13	Galapagos Nv	Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
WO2014095798A1 (en) *	2012-12-20	2014-06-26	Galapagos Nv	Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)
GB201319677D0 (en) *	2013-11-07	2013-12-25	Eth Z Rich	Cyclopropanation
GB201411241D0 (en) *	2014-06-25	2014-08-06	Galapagos Nv	Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) *	2015-04-23	2015-06-10	Galapagos Nv	Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP3594221B1 (en)	2017-03-06	2021-06-30	Shanghai Institute of Materia Medica, Chinese Academy of Sciences	Gpr84 receptor antagonist and use thereof
EP3403649A1 (en)	2017-05-16	2018-11-21	Bayer Pharma Aktiengesellschaft	Inhibitors and antagonists of gpr84 for the treatment of endometriosis
MX2020004810A (es)	2017-11-15	2020-08-13	Galapagos Nv	Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas.
GEP20247585B (en)	2019-12-19	2024-01-25	Bayer Ag	Furoindazole derivatives
WO2021123394A1 (en)	2019-12-20	2021-06-24	University Of Copenhagen	G protein-coupled receptor modulators and a pharmaceutical composition
WO2022112186A1 (en)	2020-11-24	2022-06-02	Galapagos Nv	Compound for use in and methods of treatment of fibrotic diseases
CA3211437A1 (en)	2021-02-23	2022-09-01	Bayer Aktiengesellschaft	Furoindazole derivatives as gpr84 antagonists
CN115109072A (zh) *	2021-03-18	2022-09-27	武汉人福创新药物研发中心有限公司	一种gpr84拮抗剂及其制备方法和用途
WO2022218372A1 (zh) *	2021-04-14	2022-10-20	武汉人福创新药物研发中心有限公司	一种二氢嘧啶并异喹啉酮类衍生物及用途
EP4330260A1 (en)	2021-04-29	2024-03-06	Bayer Aktiengesellschaft	Furoindazole derivatives as antagonists or inhibitors of gpr84
WO2022263676A1 (en)	2021-06-18	2022-12-22	University Of Copenhagen	Polysubstituted 4-hydroxypyridine and 4-hydroxyquinoline derivatives as gpr84 antagonists
EP4361151A1 (en)	2021-06-21	2024-05-01	Wuhan Humanwell Innovative Drug Research and Development Center Limited Company	Tricyclic compound used as gpr84 antagonist
CN115611944A (zh)	2021-07-15	2023-01-17	中国科学院上海药物研究所	不对称gpr84拮抗剂及其用途
WO2023076668A1 (en) *	2021-10-29	2023-05-04	Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College	Compositions and methods for treatment of cancer
WO2024083705A1 (en)	2022-10-18	2024-04-25	Bayer Aktiengesellschaft	Furoindazole derivatives for the treatment of pain

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2720085A1 (de)	1977-05-05	1978-11-16	Hoechst Ag	Pyrimido(6,1-a)isochinolin-2-on- derivate
ATE311884T1 (de) *	1997-07-12	2005-12-15	Cancer Rec Tech Ltd	Cyclin-abhängige-kinase inhibierende purinderivate
MXPA01009847A (es) *	1999-03-31	2003-06-24	Vernalis Ltd	Derivados de perimido (6, 1 - a) isoquinolin -4- ona.
JP2007525475A (ja) *	2003-07-08	2007-09-06	スミスクライン・ビーチャム・コーポレイション	新規化学化合物
WO2005050225A2 (en)	2003-10-31	2005-06-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
EP1929310A2 (en) *	2005-09-02	2008-06-11	Arena Pharmaceuticals, Inc.	Human g protein-coupled receptor and modulators thereof for the treatment of atherosclerosis and atherosclerotic disease and for the treatment of conditions related to mcp-1 expression
US7989461B2 (en)	2005-12-23	2011-08-02	Amgen Inc.	Substituted quinazolinamine compounds for the treatment of cancer
US8217177B2 (en) *	2006-07-14	2012-07-10	Amgen Inc.	Fused heterocyclic derivatives and methods of use
RU2473549C2 (ru)	2008-07-31	2013-01-27	Дженентек, Инк.	Пиримидиновые соединения, композиции и способы применения
JP2011088847A (ja)	2009-10-21	2011-05-06	Takeda Chem Ind Ltd	三環性化合物およびその用途
AR089284A1 (es)	2011-12-22	2014-08-13	Galapagos Nv	Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
AU2012372019B2 (en)	2011-12-22	2017-06-15	Connexios Life Sciences Pvt. Ltd.	Cyclic amide derivatives as inhibitors of 11 - beta - hydroxysteroid dehydrogenase and uses thereof
JO3398B1 (ar)	2011-12-22	2019-10-20	Novartis Ag	مشتقات 2،3- ثانى هيدرو- بنزو[1,4] أوكسازين والمركبات المتعلقة بها كمثبطات كيناز فسفواينوسيتيد-3 (pi3k) لمعالجة على سبيل المثال التهاب المفاصل الروماتيدي
RU2672468C1 (ru)	2011-12-22	2018-11-15	Конекшис Лайф Сайенсиз Пвт. Лтд.	Производные аза-адамантанов и их применение
WO2014095798A1 (en)	2012-12-20	2014-06-26	Galapagos Nv	Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)

2012
- 2012-12-17 AR ARP120104774A patent/AR089284A1/es active IP Right Grant
- 2012-12-20 DK DK17184834.4T patent/DK3378862T3/da active
- 2012-12-20 LT LTEP17184834.4T patent/LT3378862T/lt unknown
- 2012-12-20 PE PE2014000988A patent/PE20141685A1/es active IP Right Grant
- 2012-12-20 PL PL17184834T patent/PL3378862T3/pl unknown
- 2012-12-20 UA UAA201408294A patent/UA111767C2/uk unknown
- 2012-12-20 SG SG11201403169PA patent/SG11201403169PA/en unknown
- 2012-12-20 TW TW101148765A patent/TWI567073B/zh active
- 2012-12-20 CA CA2859578A patent/CA2859578C/en active Active
- 2012-12-20 HU HUE12812237A patent/HUE12812237T4/hu unknown
- 2012-12-20 US US13/721,788 patent/US8927543B2/en active Active
- 2012-12-20 PT PT128122371T patent/PT2794604T/pt unknown
- 2012-12-20 EP EP22155038.7A patent/EP4019519A1/en active Pending
- 2012-12-20 KR KR1020147020306A patent/KR102012268B1/ko active IP Right Grant
- 2012-12-20 CN CN201280061536.3A patent/CN103998448B/zh active Active
- 2012-12-20 DK DK12812237.1T patent/DK2794604T3/da active
- 2012-12-20 HR HRP20220456TT patent/HRP20220456T1/hr unknown
- 2012-12-20 WO PCT/EP2012/076275 patent/WO2013092791A1/en active Application Filing
- 2012-12-20 EP EP12812237.1A patent/EP2794604B1/en active Active
- 2012-12-20 JP JP2014547997A patent/JP6062453B2/ja active Active
- 2012-12-20 EP EP17184834.4A patent/EP3378862B1/en active Active
- 2012-12-20 PT PT171848344T patent/PT3378862T/pt unknown
- 2012-12-20 PL PL12812237T patent/PL2794604T3/pl unknown
- 2012-12-20 MX MX2014007363A patent/MX351681B/es active IP Right Grant
- 2012-12-20 LT LTEP12812237.1T patent/LT2794604T/lt unknown
- 2012-12-20 EA EA201491245A patent/EA023826B1/ru not_active IP Right Cessation
- 2012-12-20 AU AU2012357067A patent/AU2012357067B2/en active Active
- 2012-12-20 ES ES17184834T patent/ES2911449T3/es active Active
- 2012-12-20 BR BR112014015142-3A patent/BR112014015142B1/pt active IP Right Grant
- 2012-12-20 ES ES12812237.1T patent/ES2643379T3/es active Active
- 2012-12-20 SI SI201231087T patent/SI2794604T1/sl unknown
- 2012-12-20 IN IN1033MUN2014 patent/IN2014MN01033A/en unknown
- 2012-12-20 SI SI201231991T patent/SI3378862T1/sl unknown
- 2012-12-21 UY UY0001034545A patent/UY34545A/es unknown
2014
- 2014-01-06 US US14/148,057 patent/US9255095B2/en active Active
- 2014-05-26 PH PH12014501178A patent/PH12014501178B1/en unknown
- 2014-06-18 IL IL233212A patent/IL233212B/en active IP Right Grant
- 2014-06-19 NI NI201400060A patent/NI201400060A/es unknown
- 2014-06-20 CL CL2014001664A patent/CL2014001664A1/es unknown
- 2014-06-23 ZA ZA2014/04607A patent/ZA201404607B/en unknown
- 2014-06-24 CR CR20140305A patent/CR20140305A/es unknown
- 2014-07-22 CO CO14158655A patent/CO7010835A2/es unknown
2015
- 2015-03-02 HK HK15102096.2A patent/HK1201528A1/zh unknown
- 2015-12-11 US US14/966,879 patent/US10047083B2/en active Active
2017
- 2017-09-18 HR HRP20171404TT patent/HRP20171404T1/hr unknown
- 2017-10-11 CY CY20171101053T patent/CY1119434T1/el unknown
2018
- 2018-02-18 IL IL257581A patent/IL257581A/en unknown
- 2018-05-04 US US15/971,245 patent/US11220499B2/en active Active
2021
- 2021-11-12 US US17/454,712 patent/US20220227751A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US11220499B2 (en)	2022-01-11
PL2794604T3 (pl)	2017-12-29
HRP20171404T1 (hr)	2017-11-17
ES2911449T3 (es)	2022-05-19
CY1119434T1 (el)	2018-03-07
US20140121204A1 (en)	2014-05-01
EA023826B1 (ru)	2016-07-29
US8927543B2 (en)	2015-01-06
CN103998448B (zh)	2016-04-20
ES2643379T3 (es)	2017-11-22
EP4019519A1 (en)	2022-06-29
HRP20220456T1 (hr)	2022-05-27
KR102012268B1 (ko)	2019-08-21
US10047083B2 (en)	2018-08-14
CA2859578A1 (en)	2013-06-27
AU2012357067A1 (en)	2014-07-10
IL233212A0 (en)	2014-08-31
CA2859578C (en)	2020-03-10
US20130165437A1 (en)	2013-06-27
BR112014015142A2 (pt)	2017-06-13
US20160244442A1 (en)	2016-08-25
ZA201404607B (en)	2020-02-26
DK2794604T3 (da)	2017-11-06
MX351681B (es)	2017-10-25
AU2012357067B2 (en)	2017-01-05
EA201491245A1 (ru)	2014-10-30
CO7010835A2 (es)	2014-07-31
US20220227751A1 (en)	2022-07-21
PH12014501178A1 (en)	2014-10-20
NZ626473A (en)	2016-03-31
TWI567073B (zh)	2017-01-21
EP3378862A1 (en)	2018-09-26
WO2013092791A1 (en)	2013-06-27
KR20140117427A (ko)	2014-10-07
HUE12812237T4 (hu)	2017-12-28
HK1201528A1 (zh)	2015-09-04
ES2643379T9 (es)	2018-01-05
JP2015500861A (ja)	2015-01-08
IL233212B (en)	2018-03-29
SI2794604T1 (sl)	2017-12-29
BR112014015142B1 (pt)	2022-03-29
EP2794604A1 (en)	2014-10-29
LT3378862T (lt)	2022-04-25
TW201331201A (zh)	2013-08-01
PL3378862T3 (pl)	2022-05-16
UA111767C2 (uk)	2016-06-10
IN2014MN01033A (zh)	2015-05-01
AR089284A1 (es)	2014-08-13
US20190002458A1 (en)	2019-01-03
LT2794604T (lt)	2017-10-25
PE20141685A1 (es)	2014-11-25
CL2014001664A1 (es)	2014-10-03
MX2014007363A (es)	2014-08-01
CR20140305A (es)	2014-07-23
EP3378862B1 (en)	2022-03-16
JP6062453B2 (ja)	2017-01-18
PT2794604T (pt)	2017-10-23
DK3378862T3 (da)	2022-04-11
EP2794604B1 (en)	2017-09-13
IL257581A (en)	2018-04-30
CN103998448A (zh)	2014-08-20
NI201400060A (es)	2015-04-27
UY34545A (es)	2013-07-31
SI3378862T1 (sl)	2022-05-31
PH12014501178B1 (en)	2014-10-20
PT3378862T (pt)	2022-04-11
US9255095B2 (en)	2016-02-09

Publication	Publication Date	Title
IL257581A (en)	2018-04-30	New dihydropyrimidineisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders
HK1249507A1 (zh)	2018-11-02	用於治療炎性障礙的新化合物及其藥物組合物
IL239355A0 (en)	2015-07-30	Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
EP2552433A4 (en)	2013-11-06	COMPOSITIONS AND METHODS OF TREATING SOMATOSENSORY DISEASES
HK1198909A1 (zh)	2015-06-19	用於治療肝臟疾病和障礙的組合物和方法
HK1197235A1 (zh)	2015-01-09	二氫吡唑、其藥物組合物及其治療生育障礙的用途
EP2675275A4 (en)	2015-03-11	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS
HK1207293A1 (zh)	2016-01-29	用於治療炎症或免疫疾病的組合物
ZA201408045B (en)	2016-03-30	Compositions and methods for the treatment of inflammation and lipid disorders
EP2767286A4 (de)	2014-09-17	Orale pharmazeutische zusammensetzung zur behandlung von entzündlichen magen-darm-erkrankungen